Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026

Core Insights - The Chief Scientific Officer of Scholar Rock Holding Corp, Mo Qatanani, sold 14,898 shares on January 22, 2026, for approximately $695,937, but this should not concern investors as it was part of a pre-scheduled trading plan [1][4]. Transaction Summary - The shares sold were part of a Rule 10b5-1 trading plan, indicating that the sale was pre-arranged and not a spontaneous decision [4]. - After the transaction, Qatanani retains direct ownership of 85,660 shares, which represents 21% of total holdings [5]. Company Overview - Scholar Rock Holding Corporation is a clinical-stage biotechnology company focused on developing therapies for severe diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and anemia [3]. - The company's current market capitalization is $4.52 billion, with a net income of -$353.43 million [2]. Future Plans - Scholar Rock plans to launch its key product candidate, apitegromab, in the U.S. and European markets, pending regulatory approvals [5]. - Apitegromab is positioned as the world's first and only muscle-targeted treatment for spinal muscular atrophy (SMA), a severe genetic neuromuscular disease [6].